Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market Global Report 2026

The clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market size has grown exponentially in recent years. It will grow from $5.64 billion in 2025 to $6.93 billion in 2026 at a compound annual growth rate (CAGR) of 22.8%. The growth in the historic period can be attributed to advancement in genome sequencing technologies, emergence of early gene therapy research programs, increasing funding for rare disease research, development of viral vector delivery systems, growing academic research in molecular genetics.

The clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market size is expected to see exponential growth in the next few years. It will grow to $15.85 billion in 2030 at a compound annual growth rate (CAGR) of 23%. The growth in the forecast period can be attributed to expansion of personalized medicine and gene based therapeutics, increasing regulatory approvals for gene editing therapies, growth in clinical trials for oncology and genetic disorders, advancement in in vivo delivery technologies, rising investment in next generation genome engineering platforms. Major trends in the forecast period include rising adoption of precision gene correction therapies for rare genetic disorders, increasing clinical focus on programmable nuclease based therapeutic platforms, expansion of personalized regenerative medicine pipelines, growing use of advanced delivery vectors for targeted gene editing, increasing integration of high fidelity gene editing validation and safety screening frameworks.

The increasing prevalence of genetic and chronic diseases is expected to propel the growth of the clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market going forward. Genetic and chronic diseases refer to medical conditions caused by inherited genetic mutations or long-term health disorders that persist over time, including sickle cell anemia, cystic fibrosis, diabetes, cancer, and cardiovascular diseases. The increasing prevalence of genetic and chronic diseases is driven by aging populations, as older individuals are more likely to develop long-term health conditions such as cancer, diabetes, cardiovascular diseases, and age-related genetic disorders. CRISPR-based gene editing therapeutics help treat genetic and chronic diseases by precisely modifying disease-causing genes to correct mutations and improve long-term treatment outcomes for conditions such as cancer, diabetes, cystic fibrosis, and sickle cell anemia. For instance, in October 2025, according to the Cystic Fibrosis Trust, a UK-based charity dedicated to supporting people with cystic fibrosis, cystic fibrosis patient registrations increased from 11,148 in 2022 and 11,318 in 2023 to 11,381 in 2024, reflecting continued year-over-year growth. Therefore, the increasing prevalence of genetic and chronic diseases is driving the growth of the clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market.

Leading companies operating in the clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market are focusing on developing innovative therapies, such as ex vivo gene-editing therapy, to treat inherited genetic disorders and improve long-term patient outcomes. Ex vivo gene-editing therapy is a treatment approach in which a patient’s cells are removed from the body, genetically modified or corrected in a laboratory using gene-editing technologies such as CRISPR/Cas9, and then infused back into the patient to help treat or potentially cure diseases by addressing the underlying genetic defect. For example, in January 2024, Vertex Pharmaceuticals, a US-based biotechnology company, received U.S. Food and Drug Administration (FDA) approval for CASGEVY (exagamglogene autotemcel [exa-cel]) for the treatment of transfusion-dependent beta thalassemia (TDT) in patients aged 12 years and older. CASGEVY is a one-time CRISPR/Cas9 gene-edited cell therapy designed to address the underlying genetic cause of TDT and reduce dependence on chronic blood transfusions. The approval followed the earlier FDA approval of CASGEVY for sickle cell disease and marked a significant advancement in the application of genome-editing therapeutics for inherited blood disorders. Additionally, Vertex established a network of authorized treatment centers across the U.S. to support the administration of CASGEVY to eligible patients requiring specialized stem cell transplantation procedures.

In July 2025, Eli Lilly and Company, a US-based pharmaceutical and healthcare company, acquired Verve Therapeutics Inc. for an undisclosed amount. Through this acquisition, Eli Lilly and Company aimed to strengthen its cardiometabolic and genetic medicine portfolio by integrating Verve Therapeutics Inc.’s in vivo gene-editing therapies, thereby advancing the development of one-time treatments for patients with high cardiovascular risk and chronic cholesterol-related diseases. Verve Therapeutics Inc. is a US-based biotechnology company that specializes in developing CRISPR-based gene-editing therapeutics.

Major companies operating in the clustered regularly interspaced short palindromic repeats (crispr)-based gene editing therapeutic market are Novartis AG; AstraZeneca PLC; Beam Therapeutics Inc.; CRISPR Therapeutics AG; Sana Biotechnology Inc.; Wave Life Sciences Ltd.; Editas Medicine Inc.; EditCo Bio Inc.; Cellectis S.A.; Metagenomi Inc.; Arbor Biotechnologies Inc.; Intellia Therapeutics Inc.; Caribou Biosciences Inc.; Mammoth Biosciences Inc.; Korro Bio Inc.; Scribe Therapeutics Inc.; Allogene Therapeutics Inc.; Prime Medicine Inc.

North America was the largest region in the clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market consists of revenues earned by entities by providing services such as gene editing research, therapeutic development, clinical trial support, genomic analysis, and cell engineering services. The market value includes the value of related goods sold by the service provider or included within the service offering. The clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market also includes sales of guide RNA products, gene delivery vectors, engineered cells, and laboratory reagents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The clustered regularly interspaced short palindromic repeats (crispr)-based gene editing therapeutic market research report is one of a series of new reports that provides clustered regularly interspaced short palindromic repeats (crispr)-based gene editing therapeutic market statistics, including clustered regularly interspaced short palindromic repeats (crispr)-based gene editing therapeutic industry global market size, regional shares, competitors with a clustered regularly interspaced short palindromic repeats (crispr)-based gene editing therapeutic market share, detailed clustered regularly interspaced short palindromic repeats (crispr)-based gene editing therapeutic market segments, market trends and opportunities, and any further data you may need to thrive in the clustered regularly interspaced short palindromic repeats (crispr)-based gene editing therapeutic industry. This clustered regularly interspaced short palindromic repeats (crispr)-based gene editing therapeutic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.